The advanced wound-care market is forecast to grow 4% per annum during the next five years, and that is getting the attention of major players in the healthcare sector. For example, German giant Bayer, which does not have a dedicated wound-care division, has let it be known that it is keen to invest in this market. In the United Kingdom, Shire Pharmaceutical entered the sector in 2011 when it acquired Advanced Biohealing for £450 million, giving it a platform to absorb other wound-care related assets. Expect more of the same in 2013, reports business analyst James Knott of Catalyst Corporate Finance.
The usual suspects are fueling growth in wound care products: obesity, an ageing population and increased incidence of type 2 diabetes. Advanced wound care products treat complex conditions such as diabetic, venous and pressure ulcers.
A lack of clinical evidence showing the efficacy or cost effectiveness of treatment alternatives is a headache for healthcare authorities across the globe, many of whom are wrestling with austerity measures, writes Knott. “This means that major players will continue to invest heavily in R&D to try and develop new, more-effective treatments and meet market needs, but alongside this there will be a significant amount of M&A [activity],” adds Knott.
At MEDTEC UK next month, a conference session will be devoted to advanced wound-care technologies on 2 May. Also at the event, Knott will participate in a roundtable on IP strategies. MEDTEC UK comes to Olympia London on 1 and 2 May.